Ancient herbal formula jingfang granules put to the test against IBS diarrhea
NCT ID NCT07688161
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This clinical trial investigates whether Jingfang Granules, a traditional Chinese herbal medicine, can safely and effectively reduce symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D) in people with a specific pattern called cold-dampness disturbing spleen syndrome. The study compares Jingfang Granules to the standard drug trimebutine over 4 weeks of treatment, followed by 12 weeks of follow-up. Researchers will measure changes in IBS severity, stool consistency, quality of life, and explore how the treatment might work by looking at immune and gut barrier markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Jingfang Granules (Chinese herbal formula)
- What this could lead to
- If effective, Jingfang Granules could offer a new, well-tolerated treatment option for people with diarrhea-predominant IBS who have cold-dampness spleen syndrome.
- What could go wrong
- This is a Phase 3 trial with 106 participants, so results may not apply to all IBS patients. Herbal remedies can vary in quality and may cause side effects or interact with other medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing First Hospitai
Nanjing, Jiangsu, 210006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.